PharVision Advisers’s Schneider National SNDR Stock Holding History

PharVision Advisers’s Portfolio SNDR Stock Details SNDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,716	Closed	-$438K	–	981
2025 Q3	$438K	Buy	+20,716	New	+$507K	0.25%	47

Other funds holding SNDR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFA

Blueprint Financial Advisors Greensboto, North Carolina $900M AUM 38.9% 1-Year Est. Return

BIP

Blueprint Investment Partners Greensboro, North Carolina $1.2B AUM 35.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DRZID

DePrince Race & Zollo Inc (DRZ) Winter Park, Florida $5.96B AUM 38.5% 1-Year Est. Return

PharVision Advisers's SNDR Position: Q4 2025 in Review

PharVision Advisers sold out of Schneider National (SNDR) in Q4 2025, closing a stake of 20,716 shares — an estimated $438K sold.

PharVision Advisers first reported a position in SNDR in Q3 2025 and held it in 1 quarter. The position peaked at $438K in Q3 2025. 291 funds tracked by Wall St. Rank hold SNDR as of Q4 2025.

PharVision Advisers reported no remaining Schneider National position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 20,716 Schneider National shares in Q4 2025, an estimated $438K.
PharVision Advisers first reported a position in Schneider National in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Schneider National position peaked at $438K in Q3 2025.
291 funds tracked by Wall St. Rank held Schneider National as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.